This work demonstrates a new microfluidic Ames test assessing mutagenicity in a resource-efficient way.
This work presents the first demonstration of a tube‐based droplet microfluidic implementation of the Ames test, bridging single‐droplet resolution with regulatory genotoxicity testing. The Ames test is a cornerstone assay for detecting mutagenicity, but conventional plate‐ and well‐based formats suffer from high reagent consumption, low throughput, and limited automation. We report a droplet‐based microfluidic Ames test assay using Salmonella typhimurium TA98, combining nanoliter compartmentalization with multiparameter optical detection. Cell density screening identified an optimal inoculum range of 10 6 –10 7 cells/mL that maximized sensitivity while limiting spontaneous revertants. Dose–response analysis with the reference mutagen 4‐nitro‐o‐phenylenediamine (4‐NOPD) revealed clear increases in the fraction of droplets with growth of revertants, followed by a cytotoxic suppression at ≥ 8 μg/mL. A threshold‐based evaluation enabled robust quantification of stochastic mutation events at single‐droplet resolution. Compared with the classical fluctuation assay, the microfluidic format reduced reagent consumption by > 90%, generated statistically powerful datasets within 48 h, and eliminated subjective scoring. This study establishes segmented‐flow microfluidics as a scalable, sensitive, and resource‐efficient platform for mutagenicity testing, with applications in regulatory toxicology, environmental monitoring, and high‐throughput chemical screening.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: